BRAF and thyroid cancer: Accordingly, we found that serum Cyfra 21.1, the soluble fragment of CK19, was increased in thyroid cancer patients with distant metastasis and BRAF V600E mutation, indicating that serum Cyfra 21.1 levels in this group may facilitate disease monitoring; however, further studies are needed to validate this finding.